The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Brewing T-cell therapies for leukemia and lymphoma
David Maloney, MD, PhD, from Seattle Cancer Care Alliance, USA gives an overview of current trials using CAR T-cells in leukemia and lymphoma treatment at the European Haematological Association (EHA) 2017 in Madrid, Spain. He highlights three specific companies working on producing similar therapies, Kite, Juno and Novartis, using costimulatory domains with retroviruses or lentiviruses. Despite being restricted to patients who have already failed other therapies, CAR T- cell mediated therapy has shown encouraging results so far.
